UMN Pharma Of Japan To Start Phase I/II Trials For Avian Flu Vaccine
This article was originally published in PharmAsia News
Akita, Japan-based UMN Pharma, will start Phase I/II trials for avian flu vaccine UMN-501 in mid-June. Unlike current flu vaccines derived from embryonated chicken eggs, UMN-501 is derived from a recombinant protein, which will enable production of large quantities of vaccine in a short time period. UMN Pharma acquired an exclusive license to manufacture and sell recombinant protein-based influenza vaccines in Japan from the U.S. firm Protein Sciences Corporation. (Click here for more - Japanese language
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.